---
title: "CJC-1295 with DAC: what sources report"
url: https://humanpeptides.fyi/peptides/cjc-1295-dac
site: humanpeptides.fyi
last_reviewed: 2026-10-11
---
# CJC-1295 with DAC
> humanpeptides.fyi makes no claims of its own. Every statement below reports what a cited source says, with its link. Not medical advice.
CJC-1295 with DAC: Long-acting GHRH analogue (modified GRF 1-29) with a Drug Affinity Complex that binds albumin, giving ~6-8 day half-life and sustained GH/IGF-1 release. The sources cited here most often discuss it for: Days-long GH and IGF-1 rise; Visceral fat, trial halted; Sleep, muscle and fat, unproven claims. Evidence label: Early human.
## At a glance
- **Type:** Peptide
- **Family:** Growth Hormone Axis
- **Evidence label:** Early human (3 of 5)
- **Regulatory status:** FDA listed CJC-1295 among nominated compounding substances that may present significant safety risks, citing serious adverse events including increased heart rate and a systemic vasodilatory reaction, and the nomination was later withdrawn.
- **Goals discussed:** Hormones & Fertility, Fat Loss & Metabolism, Sleep, Muscle & Tone
- **Also called:** DAC:GRF, CJC-1295 with DAC
- **Last reviewed:** 2026-10-11
## What is CJC-1295 with DAC?
- Long-acting GHRH analogue (modified GRF 1-29) with a Drug Affinity Complex that binds albumin, giving ~6-8 day half-life and sustained GH/IGF-1 release; not FDA-approved, development halted in 2006. Sources: ,
**Regulatory status:** FDA listed CJC-1295 among nominated compounding substances that may present significant safety risks, citing serious adverse events including increased heart rate and a systemic vasodilatory reaction, and the nomination was later withdrawn. Source:
## What is CJC-1295 with DAC researched for?
### 1. Days-long GH and IGF-1 rise
- Raises GH 2-10 fold for >6 days and IGF-1 1.5-3 fold for 9-11 days after a single dose; weekly/biweekly dosing kept IGF-1 elevated up to 28 days (human RCT, healthy adults) Sources: ,
- Goals: [Hormones & Fertility](https://humanpeptides.fyi/objectives/hormones)
### 2. Visceral fat, trial halted
- Was tested for reducing visceral fat in HIV lipodystrophy (phase 2, n=192), but trial halted, no efficacy published (human trial, stopped) Sources: ,
- Goals: [Fat Loss & Metabolism](https://humanpeptides.fyi/objectives/fat-loss)
### 3. Sleep, muscle and fat, unproven claims
- Claimed sleep, muscle and abdominal fat-loss benefits are extrapolated from GH/IGF-1 elevation and GHRH research; no dedicated CJC-1295 outcome studies (practitioner/vendor review) Sources:
- Goals: [Sleep](https://humanpeptides.fyi/objectives/sleep), [Muscle & Tone](https://humanpeptides.fyi/objectives/muscle), [Fat Loss & Metabolism](https://humanpeptides.fyi/objectives/fat-loss)
## What do researchers and users say about CJC-1295 with DAC?
> "After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d."
>
> Teichman SL, et al., Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (J Clin Endocrinol Metab, 2006).
Context: Two randomized, placebo-controlled, ascending-dose trials in healthy adults aged 21 to 61.
> "FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction."
>
> U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
Context: FDA's safety assessment of CJC-1295 as a nominated compounding substance; the nomination was later withdrawn.
## What side effects of CJC-1295 with DAC are reported?
- Injection-site pain/swelling/itching, induration, headache, diarrhea, hypertension (Teichman RCTs); also flushing, water retention, insomnia reported Sources: ,
- A trial participant died of myocardial infarction after 11th dose (attributed to pre-existing coronary disease), program stopped Sources:
- Serious adverse events including increased heart rate and a systemic vasodilatory reaction (FDA assessment) Sources:
- Possible immune reactions (immunogenicity) and peptide impurity problems in compounded products (FDA assessment) Sources:
## What do peptide guides say about CJC-1295 with DAC?
- **Dr. Axe:** Dr. Axe's guide lists the CJC-1295 and ipamorelin pairing as research-only with insufficient evidence, notes the cited human study tested CJC-1295 alone, and says WADA bans CJC-1295.
- **PepEdHub:** PepEdHub explains the DAC version binds albumin, stretching its half-life to roughly 6 to 8 days, and that its more sustained GH release may raise IGF-1 more than the short-acting form.
- **Seek Peptides:** Seek Peptides groups CJC-1295 with and without DAC in one entry aimed at sustained GH elevation, promoting it for muscle, recovery, sleep and fat loss, usually paired with ipamorelin.
## What does the research say, system by system?
### Body & tissues
- No direct tissue outcome data found
### Hormones & physiology
- Sustained GH and IGF-1 elevation, half-life 5.8-8.1 days (human RCT) Sources:
- FDA reviewed CJC-1295 for compounding in 2024 PCAC presentation Sources:
### Brain, mood & sleep
- No direct CJC-1295 sleep study; parent hormone GHRH (intranasal, 1999 human study) increased slow-wave and REM sleep, extrapolated to CJC-1295 (indirect) Sources:
### Weight & metabolism
- Visceral obesity trial halted before results (human) Sources:
### Muscle
- No outcome data; theorized via GH/IGF-1 elevation Sources:
### Also notable
- WADA lists CJC-1295 as an S2 prohibited substance; a 2005 rat study and GHRH-knockout mouse study support GH release and normal growth (animal) Sources:
## How strong is the evidence for CJC-1295 with DAC?
**Early human** (3 of 5). Small human PK/PD RCTs showing GH/IGF-1 rise; no clinical outcome data; development abandoned
_Small, short, old, unblinded or single-group human studies._
## Questions about CJC-1295 with DAC
### What is CJC-1295 with DAC?
Long-acting GHRH analogue (modified GRF 1-29) with a Drug Affinity Complex that binds albumin, giving ~6-8 day half-life and sustained GH/IGF-1 release.
### Is CJC-1295 with DAC FDA-approved?
FDA listed CJC-1295 among nominated compounding substances that may present significant safety risks, citing serious adverse events including increased heart rate and a systemic vasodilatory reaction, and the nomination was later withdrawn.
### What is CJC-1295 with DAC researched for?
The sources cited on this page most often discuss three outcomes: Days-long GH and IGF-1 rise; Visceral fat, trial halted; Sleep, muscle and fat, unproven claims. Each line above shows what the source reports and how strong that evidence is.
### What side effects of CJC-1295 with DAC are reported?
Reported in the cited sources: Injection-site pain/swelling/itching, induration, headache, diarrhea, hypertension (Teichman RCTs); also flushing, water retention, insomnia reported; A trial participant died of myocardial infarction after 11th dose (attributed to pre-existing coronary disease), program stopped; Serious adverse events including increased heart rate and a systemic vasodilatory reaction. The list is not complete, and few listed risks does not mean a compound is safe.
### How strong is the evidence for CJC-1295 with DAC?
Evidence label: Early human. Small human PK/PD RCTs showing GH/IGF-1 rise; no clinical outcome data; development abandoned.
### What else is CJC-1295 with DAC called?
Names used for it include DAC:GRF, CJC-1295 with DAC.
### Does humanpeptides.fyi recommend CJC-1295 with DAC?
No. humanpeptides.fyi makes no claims and no recommendations of its own. It summarizes and links to what others have published and posted. Nothing here is medical advice; talk to a licensed clinician.
---
Family: [Growth Hormone Axis](https://humanpeptides.fyi/peptides?cat=gh-axis). HTML version: . Disclaimer: